Product Description
Mechanisms of Action: CYP3A4 Inhibitor
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Oral,Intravenous
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: Argentina | Australia | Austria | Belgium | Canada | Cyprus | Czech | Ecuador | Egypt | Estonia | European Medicines Agency | Finland | France | Greece | Hong Kong | Hungary | Iceland | India | Ireland | Israel | Jordan | Korea | Latvia | Lebanon | Lithuania | Luxembourg | Peru | Poland | Portugal | Romania | Russia | Serbia | Singapore | Slovakia | Slovenia | Spain | Sweden | Switzerland | United Arab Emirates | United Kingdom
Approved Indications: None
Known Adverse Events: None
Company: Astellas Pharma
Company Location: NEW YORK NY 10005
Company CEO:
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Highest Development Phases
Phase 4: Invasive Fungal Infections|Lung Transplant
Phase 3: Aspergillosis|Invasive Fungal Infections|Severe Acute Respiratory Syndrome|Invasive Pulmonary Aspergillosis|Candidiasis, Invasive|Candidemia|Acute Myeloid Leukemia|Respiratory Insufficiency|Coronavirus Infections
Phase 2: Myeloproliferative Disorders|Invasive Pulmonary Aspergillosis|Preleukemia|Neutropenia|Aspergillosis|Pulmonary Aspergillosis|Myelodysplastic Syndrome|Acute Myeloid Leukemia
Phase 1: Healthy Volunteers|Kidney Diseases
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|---|---|---|---|---|
| YJK-001 | N/A |
Not yet recruiting |
Aspergillosis|Mucormycosis |
2026-06-30 |
|
| ChiCTR2400086245 | N/A |
Not yet recruiting |
Mucormycosis|Aspergillosis |
2026-06-30 |
|
| C3791001 | P4 |
Recruiting |
Invasive Fungal Infections |
2025-06-27 |
|
| IA-DUET | P3 |
Terminated |
Aspergillosis |
2024-05-01 |